Drug Discovery World

AUGUST 28, 2024

It is approved for the first-line treatment of adult patients with unresectable or metastatic cancer, who are eligible for platinum-containing chemotherapy. I look forward to seeing the treatment combination implemented as a first-line regimen in the clinical setting.” months compared to 16.1 The median PFS of 12.5

Treatment 130

Treatment Clinical Trials Trials FDA 130

Drug Discovery World

OCTOBER 11, 2023

Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA).

Clinical Trials 130

Clinical Trials Treatment Trials FDA Approval 130

Drug Discovery World

APRIL 14, 2023

Researchers from the University of Oxford have reported findings from a Phase II clinical trial investigating the efficacy of an investigational treatment against long Covid fatigue. Clinical trial details On average, patients had symptoms of fatigue for about 18 months prior to entering the study.

Treatment 130

Treatment Trials Clinical Trials Pharmaceutical Companies 130

Drug Discovery World

OCTOBER 27, 2023

The US Food and Drug Administration (FDA) has granted clearance for Endogena’s Investigational New Drug (IND) application for EA 2351, a potential treatment for geographic atrophy (GA). The post FDA gives green light for AMD treatment trials appeared first on Drug Discovery World (DDW).

FDA 130

FDA Treatment Trials Therapies 130

Drug Discovery World

APRIL 4, 2024

EnteroBiotix, a Glasgow, UK based biotechnology company, has dosed the first patient in a clinical trial designed to evaluate EBX-102-02 for the treatment of irritable bowel syndrome (IBS). The trial will be delivered in partnership with the Functional Gut Clinic, a leading IBS diagnosis and treatment centre.

Clinical Trials 246

Clinical Trials Trials Drugs Treatment 246

Drug Discovery World

DECEMBER 16, 2022

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia. . Along with positive Phase II trial data for talquetamab , the company presented promising findings on the long-term results of daratumumab in newly diagnosed, transplant-ineligible multiple myeloma patients. .

Trials 130

Trials Treatment Clinical Trials Therapies 130

Drug Discovery World

AUGUST 9, 2024

The first patient has been dosed in a Phase I clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. The dose expansion portion of the study will evaluate treatment at the recommended Phase II dose in multiple indications.

Trials 148

Trials Pharmacokinetics Drugs Clinical Trials 148

Drug Discovery World

AUGUST 8, 2024

The first cohort of participants has been dosed in a Phase I trial MTX-474, a human IgG1 antibody designed to neutralise EphrinB2 signalling to treat fibrosis. I look forward to completion of the Phase I studies and future planned Phase II trials in systemic sclerosis and IPF, respectively.”

Treatment 148

Treatment Pharmacokinetics Trials Disease 148

Drug Discovery World

JULY 5, 2024

Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD).

Treatment 148

Treatment Medical Schools Trials Clinical Trials 148

Drug Discovery World

DECEMBER 7, 2023

A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. The post Potentially game-changing schizophrenia drug enters Phase I trials appeared first on Drug Discovery World (DDW).

Trials 300

Trials Drugs Clinical Trials Licensing 300

Drug Discovery World

OCTOBER 6, 2022

A new Alzheimer’s disease (AD) treatment has been shown to reduce clinical decline in mild cognitive impairment (MCI) due to AD and mild AD with confirmed presence of amyloid pathology in the brain. . protofibril antibody lecanemab met the primary endpoint and all key secondary endpoints in the global Phase III Clarity AD clinical trial. .

Trials 130

Trials Treatment Clinical Trials Disease 130

Drug Discovery World

JUNE 25, 2024

A new study demonstrates that AI-powered digital twin solutions can potentially replace the standard-of-care (SOC) control arm of a clinical trial. Phesi created a digital twin for chronic graft versus host disease (cGvHD) in the primary treatment setting.

Clinical Trials 148

Clinical Trials Trials Hospitals Clinical Research 148

Drug Discovery World

SEPTEMBER 15, 2022

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. Findings from the SUNLIGHT trial have revealed that the combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in overall survival compared to trifluridine/tipiracil alone.

Trials 130

Trials Treatment Clinical Trials Hospitals 130

Drug Discovery World

AUGUST 14, 2024

The US Food and Drug Administration (FDA) has approved a Phase II clinical trial for Biosyngen’s BRG01, an EBV-specific CAR-T cell therapy. This marks the first cell therapy to enter Phase lI trials in both the US and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal carcinoma.

Therapies 130

Therapies Trials Clinical Trials FDA 130

Drug Discovery World

MAY 8, 2024

Calliditas Therapeutics has announced data from the proof-of-concept Phase II trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN).

Trials 174

Trials Clinical Trials Treatment Disease 174

Drug Discovery World

JUNE 21, 2024

Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are likely to relapse.

Trials 148

Trials Compliance Clinical Trials Doctors 148

Drug Discovery World

JUNE 3, 2024

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments.

Vaccine 148

Vaccine Trials Clinical Trials Hospitals 148

Drug Discovery World

NOVEMBER 25, 2022

According to the partnership between the University of Birmingham and Acticor Biotech, the trial will take place in two hospitals in the UK: the Queen Elizabeth Hospital, Birmingham and the Northern General Hospital, Sheffield. Glenzocimab reduces clot formation and laboratory findings have been impressive.

Trials 130

Trials Treatment Hospitals Laboratories 130

Drug Discovery World

AUGUST 6, 2024

The Phase I/II AFFINITY DUCHENNE trial assessed RGX-202 in patients with Duchenne ages 1 to 11 years old. This data continues to build on the totality of evidence supporting the potential for RGX-202 to be a differentiated, best-in-class treatment for Duchenne.” Initiation of the pivotal trial is expected in the fourth quarter of 2024.

Therapies 148

Therapies Trials Treatment Clinical Trials 148

Drug Discovery World

AUGUST 27, 2024

Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. Assessing psychiatric effects of CB1 inhibition The clinical trial will enrol 120 patients across four treatment groups.

Trials 130

Trials Small Molecule Clinical Trials Treatment 130

Drug Discovery World

JULY 4, 2023

New data from Boehringer Ingelheim and Zealand Pharma has demonstrated superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment. Current treatments for obesity mainly focus on weight loss by reducing energy intake.

Drug Trials 235

Drug Trials Trials Drugs Treatment 235

Drug Discovery World

AUGUST 7, 2024

The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. It is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infection.

Drug Trials 148

Drug Trials FDA Trials Immune Response 148

Drug Discovery World

JULY 14, 2022

Biotech company Actigen has moved closer to clinical trials for rare disease treatment for Hunter syndrome, following a pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA). ? . Hunter syndrome . Official comments .

Clinical Trials 130

Clinical Trials Trials Treatment Disease 130

Drug Discovery World

JULY 12, 2024

Scientists at the University of Oxford in the UK have launched a new clinical trial to test a vaccine to protect against “devastating” Marburg virus. This is the first-in-human trial of the ChAdOx1 Marburg vaccine, which has been developed and manufactured by researchers at the University of Oxford.

Virus 148

Virus Vaccine Trials Clinical Trials 148

Drug Discovery World

NOVEMBER 8, 2023

Deepika Khedekar , Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. Tapping into the capabilities of AI One reason AI may accelerate clinical trials is its ability to rapidly process and analyse vast amounts of data.

Clinical Trials 183

Clinical Trials Trials Disease Medical Schools 183

Drug Discovery World

JUNE 24, 2024

Scientists at the Brain Tumour Research Centre of Excellence at the University of Plymouth are conducting a clinical trial to see whether using anti-retroviral medications, ritonavir and lopinavir, could help people with Neurofibromatosis 2 (NF2).

Clinical Trials 148

Clinical Trials Trials Drugs DNA 148

Drug Discovery World

JULY 24, 2024

The trial was carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics and Biomarkers (D3B) team. I am very grateful for the engaging participation by the patients in especially difficult circumstances due to the onset of the pandemic during the trial period.”

Trials 130

Trials Disease Hospitals Clinical Trials 130

Drug Discovery World

JULY 5, 2024

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University in the US. Targeted, minimally-invasive delivery AVB-101 is delivered as a one-time-only treatment using a minimally invasive, stereotactic neurosurgical procedure directly to the thalamus.

Therapies 148

Therapies Trials Clinical Trials Clinical Development 148

Drug Discovery World

DECEMBER 2, 2022

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a CBD/THC combination treatment under its Named Patient programme and other compassionate areas. The company hopes to generate additional real-world data to support an anticipated Phase III clinical trial of synthetic NanaBis in 2023.

Treatment 246

Treatment Clinical Trials Doctors Trials 246

Drug Discovery World

JANUARY 11, 2024

Verge Genomics has initiated a Phase Ib proof-of-concept study for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS) with VRG50635. ” The post AI-discovered ALS drug trial uses unique remote monitoring appeared first on Drug Discovery World (DDW).

Drug Trials 246

Drug Trials Trials Small Molecule Clinical Trials 246

Drug Discovery World

JULY 2, 2024

The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM). Credit: NIAID and CDC.

Virus 148

Virus Trials Clinical Trials Laboratories 148

Drug Discovery World

MAY 17, 2024

Deepika Khedekar , Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. MIT research 4 tells us a hard truth: about 95% of these trials fall short, leaving behind a trail of broken hopes for cancer patients each year.

Trials 148

Trials Clinical Trials Treatment Research 148

Drug Discovery World

JANUARY 8, 2024

Milan-based Newron Pharmaceuticals has reported “exceptional” one-year results from study 014/15 into evenamide as an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS). These results should lead to expediting the conduct of a placebo-controlled international trial to replicate these results.”

Treatment 148

Treatment Drugs Laboratories Pharmaceuticals 148

Drug Discovery World

JANUARY 18, 2024

The results, together with the data from the recent LPS human challenge trial, further support the strategic expansion of the Phase II ready POLB 001 to treat and prevent cancer immunotherapy-induced CRS. Reductions were seen in all serum proinflammatory cytokines tested.

Treatment 163

Treatment Clinical Trials Immune Response Therapies 163

Drug Discovery World

APRIL 11, 2023

Owing to the complexity of severe asthma, many patients have unclear or multiple drivers of airway inflammation resulting in some patients not responding to the current standard of treatment, and being at increased risk of asthma attacks, hospitalisations, and a poor quality of life 3,4,5,6. Final draft guidance is subject to appeal.

Treatment 246

Treatment Clinical Trials Trials Science 246

Drug Discovery World

JULY 8, 2024

Biopharmaceutical company Syncromune has had its lead-candidate for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) granted Fast Track designation by the FDA. We look forward to initiating trials at multiple US sites later this year to expand our efforts to develop the SYNC-T SV-102 Therapy.”

FDA 148

FDA Treatment Therapies Vaccine 148

Drug Discovery World

JUNE 19, 2024

Having a more detailed understanding of sepsis at a molecular level could identify those who would benefit from different therapies, helping to design rapid tests, organise clinical trials, and develop targeted treatments based on the individual immune response.

Immune Response 163

Immune Response Treatment Regulations Therapies 163